Seres Therapeutics (MCRB) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
March 16, 2017 7:00 AM EDT- Positive SER-109 Type B FDA meeting -
- Company to initiate new Phase 2 SER-109 clinical trial that, as agreed to by the FDA, may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements -
- Continued pipeline progress with both SER-287 and SER-262 Phase 1b studies; Both data read-outs expected in the second half of 2017 -
- Conference call at 8 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ:... More
Seres Therapeutics to Initiate New SER-109 Clinical Study
March 16, 2017 7:00 AM EDTPositive SER-109 Type B FDA meeting
Seres and FDA reach agreement on key design elements of a new SER-109 Phase 2 study in patients with multiply recurrent C. difficile infection
New trial may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements
Conference call at 8 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced plans to initiate a new SER-109 Phase 2 clinical... More
